Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Chemotherapy-induced bladder cancer.
Nilsson S, Ullén A. Nilsson S, et al. Among authors: ullen a. Scand J Urol Nephrol Suppl. 2008 Sep;(218):89-92. doi: 10.1080/03008880802291832. Scand J Urol Nephrol Suppl. 2008. PMID: 18815922 Review. No abstract available.
Prostate cancer cell lines lack amplification: overexpression of HER2.
Ullén A, Lennartsson L, Harmenberg U, Lennernäs B, Majumder K, Holmberg AR, Nilsson S, Elmberger GP. Ullén A, et al. Acta Oncol. 2005;44(5):490-5. doi: 10.1080/02841860510029888. Acta Oncol. 2005. PMID: 16118083
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Ullén A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kälkner KM, Lennernäs B, Nilsson S. Ullén A, et al. Acta Oncol. 2005;44(6):644-50. doi: 10.1080/02841860510029617. Acta Oncol. 2005. PMID: 16165924
High dose-rate brachytherapy of prostate cancer utilising Iridium-192 after-loading technique: technical and methodological aspects.
Edgren M, Ekelund AM, Albertsson P, Lundberg LM, Ullen A, Levitt S, Nilsson S, Lennernäs B. Edgren M, et al. Among authors: ullen a. Int J Oncol. 2006 Dec;29(6):1517-24. doi: 10.3892/ijo.29.6.1517. Int J Oncol. 2006. PMID: 17088991
Current status of prognostic immunohistochemical markers for urothelial bladder cancer.
Rosenblatt R, Jonmarker S, Lewensohn R, Egevad L, Sherif A, Kälkner KM, Nilsson S, Valdman A, Ullén A. Rosenblatt R, et al. Among authors: ullen a. Tumour Biol. 2008;29(5):311-22. doi: 10.1159/000170878. Epub 2008 Nov 5. Tumour Biol. 2008. PMID: 18984977 Review.
Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines.
Ullen A, Schwarz S, Lennartsson L, Kalkner KM, Sandstrom P, Costa F, Lennernas B, Linder S, Nilsson S. Ullen A, et al. Scand J Urol Nephrol. 2009;43(2):98-103. doi: 10.1080/00365590802475904. Scand J Urol Nephrol. 2009. PMID: 19101859
Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.
Ullén A, Farnebo M, Thyrell L, Mahmoudi S, Kharaziha P, Lennartsson L, Grandér D, Panaretakis T, Nilsson S. Ullén A, et al. Int J Oncol. 2010 Jul;37(1):15-20. doi: 10.3892/ijo_00000648. Int J Oncol. 2010. PMID: 20514392
Management of advanced prostate cancer--new drugs.
Ullén A, Shah CH, Kirkali Z. Ullén A, et al. Acta Oncol. 2011 Jun;50 Suppl 1:137-40. doi: 10.3109/0284186X.2010.529458. Acta Oncol. 2011. PMID: 21604954 No abstract available.
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, Malmström PU; Nordic Urothelial Cancer Group. Rosenblatt R, et al. Among authors: ullen a. Eur Urol. 2012 Jun;61(6):1229-38. doi: 10.1016/j.eururo.2011.12.010. Epub 2011 Dec 13. Eur Urol. 2012. PMID: 22189383
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.
Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Björklund AC, Augsten M, Ullén A, Egevad L, Wiklund P, Nilsson S, Kroemer G, Grander D, Panaretakis T. Kharaziha P, et al. Among authors: ullen a. Cell Death Dis. 2012 Jan 26;3(1):e262. doi: 10.1038/cddis.2012.1. Cell Death Dis. 2012. PMID: 22278289 Free PMC article.
70 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page